Abstract 208P
Background
Germ cell tumours of testis is the most common cancer in young men in the western world. India has the lowest incidence globally and hence Indian data is sparse. We report the outcomes of patients with non-seminomatous germ cell tumours of testis treated at a tertiary cancer centre in South India over a period of ten years.
Methods
Patients with a histopathological diagnosis of non-seminomatous germ cell tumours of testis from Jan 1, 2006 to Dec 31, 2016 were included in the study. Patient demographics, tumour characteristics and treatment details were retrieved from case records. Kaplan-Meier method was used to estimate progression-free survival and overall survival. Cox regression model was used to analyse the prognostic factors.
Results
One hundred and nineteen patients with non-seminomatous germ cell tumours of testis of testis were included in the study. The median follow-up was 81 months. The estimated four-year overall survival and progression-free survival was 87.1% and 84.5% respectively. The four-year overall survival for good, intermediate and poor-risk groups was 93.6%,87.5% and for 52.6% respectively. The progression-free survival at four years was 91.4%, 87.8% and 47.4% for good, intermediate and poor-risk groups respectively. The presence of non-pulmonary visceral metastasis and biochemical response after chemotherapy were significant factors for overall survival and progression free survival in multivariate cox proportional hazards regression.
Conclusions
The survival figures are comparable to the rest of the world except in the poor prognostic risk group. The inferior survival noticed in this group of patients may be due to the lack of good salvage procedures. High dose chemotherapy with stem cell support may be considered more often for this group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session